Article
[Detection of RAS genes mutation using the Cobas® method in a private laboratory of pathology: Medical and economical study in comparison to a public platform of molecular biology of cancer].
Bulletin du cancer - 1 Jan 2000
Albertini Anne-Flore, Raoux Delphine, Neumann Frédéric, Rossat Stéphane, Tabet Farid, Pedeutour Florence, Duranton-Tanneur Valérie, Kubiniek Valérie, Vire Olivier, Weinbreck Nicolas
Abstract excerpt
In France, determination of the mutation status of RAS genes for predictive response to anti-EGFR targeted treatments is carried out by public platforms of molecular biology of cancer created by the French National Cancer Institute. This study aims to demonstrate the feasibility of these analyses by a private pathology laboratory (MEDIPATH) as per the requirements of accreditation. We retrospectively studied the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.